IMPROVING HEALTH THROUGH TRANSFORMATIVE THERAPIES AND DISRUPTIVE TECHNOLOGIES
Hatteras’ mission is to build transformational human medicine companies that benefit patients and the professionals who serve them.
STRIDEBIO
Developing engineered viral vectors for gene therapy using structure-inspired design of adeno-aden-associated virus (AAV) vectors that can evade neutralizing antibodies, a current limitation of existing gene therapies.
VIEW PORTFOLIOG1 THERAPEUTICS
A clinical-stage company developing small-molecule therapies to address significant unmet needs in oncology.
VIEW PORTFOLIODROPWORKS
Developing a fast, easy-to-use, and cost accessible digital PCR platform for DNA and RNA quantification.
VIEW PORTFOLIOELLIGO HEALTH RESEARCH
Providing on-demand clinical research infrastructure to enable large physician practices to offer clinical trial participation to their clients.
VIEW PORTFOLIORIBOMETRIX
Developing small molecules that target functional 3D RNA structures to treat human disease.
VIEW PORTFOLIOCONTEGO MEDICAL
Developing an integrated embolic protection platform to improve the safety and efficacy of catheter-based interventions.
VIEW PORTFOLIOORIG3N
Offering a full line of DNA tests to give you a new insight into what makes you unique.
VIEW PORTFOLIOGRAYBUG
Developing injectable therapeutics to reduce the burden of treating vision-threatening diseases.
VIEW PORTFOLIO